Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
All Keywords
【초록키워드】 COVID-19, Vaccine, vaccination, clinical trial, BCG, morbidity and mortality, protective effect, Evidence, limitation, Bacillus, country, conducted, suggested, 【제목키워드】 COVID-19, Vaccine, BCG,
【초록키워드】 COVID-19, Vaccine, vaccination, clinical trial, BCG, morbidity and mortality, protective effect, Evidence, limitation, Bacillus, country, conducted, suggested, 【제목키워드】 COVID-19, Vaccine, BCG,